Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract 5732: DXC020, a novel anti-CD54 antibody conjugate with a functional linker, exhibits potent anti-tumor efficacy

Xingyan Jiang, Tianyu Zhou, Junxiang Jia, Huihui Guo, Yuanyuan Huang, Hangbo Ye, Lingli Zhang, Jun Zheng, Lu Bai, Wenjun Li, Binbin Chen, Qingliang Yang, Robert Zhao

Cancer Res (2025) 85 (8_Supplement_1): 5732.

https://doi.org/10.1158/1538-7445.AM2025-5732

Published: 21 April 2025

View articletitled, Abstract 5732: DXC020, a novel anti-CD54 antibody conjugate with a functional linker, exhibits potent anti-tumor efficacy

Journal Articles

Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, and efficacy

Yunxia Zheng, Xiafen Wu, Junxiang Jia, Huihui Guo, Xiangfei Kong, Gengxiang Zhao, Yuanyuan Huang, Hangbo Ye, Xiaolei Liu, Yi Luo, Xiaoqiang Xie, Xia Zhou, Lu Bai, Wenjun Li, Binbin Chen, Qingliang Yang, Robert Yongxin Zhao

Cancer Res (2025) 85 (8_Supplement_1): 6742.

https://doi.org/10.1158/1538-7445.AM2025-6742

Published: 21 April 2025

View articletitled, Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, and efficacy

Journal Articles

Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations

Cancer Res (2025) 85 (8_Supplement_1): 2869.

https://doi.org/10.1158/1538-7445.AM2025-2869

Published: 21 April 2025

View articletitled, Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations

Journal Articles

Abstract 2864: DXA023-G017, a bispecific PD-1/VEGF conjugate elicits potent anti-tumor efficacy in preclinical studies

Xiaobo Cai, Wei Zheng, Junxiang Jia, Shishan Hu, Hui Xia, Qingliang Yang, Zhixiang Guo, Wei Liu, Lu Bai, Jun Zheng, Wenjun Li, Yuanyuan Huang, Zhongliang Fan, Binbin Chen, Meng Dai, Robert Zhao

Cancer Res (2025) 85 (8_Supplement_1): 2864.

https://doi.org/10.1158/1538-7445.AM2025-2864

Published: 21 April 2025

View articletitled, Abstract 2864: DXA023-G017, a bispecific PD-1/VEGF conjugate elicits potent anti-tumor efficacy in preclinical studies

Journal Articles

Abstract 1661: Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor

Jia Hu, Jun Ni, Yuanzhi Lv, Wenjun Li, Hui Zhang, Xin Li, Ying Yu, Zeyu Zhong, Jian Wang, Yang Sai, Weiguo Qing, Yongxin Ren, Michael Shi, Weiguo Su

Cancer Res (2024) 84 (6_Supplement): 1661.

https://doi.org/10.1158/1538-7445.AM2024-1661

Published: 22 March 2024

View articletitled, Abstract 1661: Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor

Journal Articles

Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation

Cancer Res (2024) 84 (6_Supplement): 5820.

https://doi.org/10.1158/1538-7445.AM2024-5820

Published: 22 March 2024

View articletitled, Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation

Journal Articles

Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Cancer Res (2024) 84 (6_Supplement): 5819.

https://doi.org/10.1158/1538-7445.AM2024-5819

Published: 22 March 2024

View articletitled, Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Journal Articles

Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Qingliang Yang, Yuanyuan Huang, Junxiang Jia, Huihui Guo, Lingli Zhang, You Zhou, Zhicang Ye, Hangbo Ye, Yifang Xu, WenJun Li, Zhiyu Zhao, Lingyao Zhao, Lu Bai, Jun Zheng, Robert Y. Zhao

Cancer Res (2024) 84 (6_Supplement): 5821.

https://doi.org/10.1158/1538-7445.AM2024-5821

Published: 22 March 2024

View articletitled, Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Journal Articles

Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

Cancer Res (2024) 84 (6_Supplement): 3147.

https://doi.org/10.1158/1538-7445.AM2024-3147

Published: 22 March 2024

View articletitled, Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

Journal Articles

Abstract 5705: Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing pCDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

Jianlin Geng, Ke Liu, Zhiyong Yu, Wenfeng Sun, Hairong Wei, Wenjun Li, Jing Lu, Juan Deng, Liqing Geng, Zhihong Liu, Zhenhai Gao, Yan Lou

Cancer Res (2024) 84 (6_Supplement): 5705.

https://doi.org/10.1158/1538-7445.AM2024-5705

Published: 22 March 2024

View articletitled, Abstract 5705: Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing pCDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

Journal Articles

Abstract 1883: A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors

Cancer Res (2024) 84 (6_Supplement): 1883.

https://doi.org/10.1158/1538-7445.AM2024-1883

Published: 22 March 2024

View articletitled, Abstract 1883: A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors

Journal Articles

Abstract 6581: DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer

Cancer Res (2024) 84 (6_Supplement): 6581.

https://doi.org/10.1158/1538-7445.AM2024-6581

Published: 22 March 2024

View articletitled, Abstract 6581: DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer

Journal Articles

Abstract 1884: DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies

Cancer Res (2024) 84 (6_Supplement): 1884.

https://doi.org/10.1158/1538-7445.AM2024-1884

Published: 22 March 2024

View articletitled, Abstract 1884: DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies

Journal Articles

Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Cancer Res (2024) 84 (6_Supplement): 1882.

https://doi.org/10.1158/1538-7445.AM2024-1882

Published: 22 March 2024

View articletitled, Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Journal Articles

Abstract 4553: DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer

Cancer Res (2024) 84 (6_Supplement): 4553.

https://doi.org/10.1158/1538-7445.AM2024-4553

Published: 22 March 2024

View articletitled, Abstract 4553: DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer

Journal Articles

Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma

Cancer Res (2020) 80 (10): 2031–2044.

https://doi.org/10.1158/0008-5472.CAN-19-1077

Published: 15 May 2020

View articletitled, Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma

Includes: Supplementary data

Journal Articles

Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells In Vivo

Dongyuan Wang, Wenjun Li, Rongtong Zhao, Longjian Chen, Na Liu, Yuan Tian, Hui Zhao, Mingsheng Xie, Fei Lu, Qi Fang, Wei Liang, Feng Yin, Zigang Li

Cancer Res (2019) 79 (8): 1769–1783.

https://doi.org/10.1158/0008-5472.CAN-18-1421

Published: 15 April 2019

View articletitled, Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells In Vivo

Includes: Supplementary data

Journal Articles

Abstract 829: Chemoprevention of oxidative stress-associated oral carcinogenesis by sulforaphane depends on NRF2 and the isothiocyanate moiety

Aixian Lan, Wenjun Li, Yao Liu, Xinyan Zhang, Shanshan Zhou, Olesya Palko, Hao Chen, Mayanga Kapita, Justin Prigge, Edward Schmidt, Xin Chen, Zheng Sun, Xiaoxin Luke Chen

Cancer Res (2016) 76 (14_Supplement): 829.

https://doi.org/10.1158/1538-7445.AM2016-829

Published: 15 July 2016

View articletitled, Abstract 829: Chemoprevention of oxidative stress-associated oral carcinogenesis by sulforaphane depends on NRF2 and the isothiocyanate moiety

Journal Articles

Abstract 4532: Functional evaluation of novel Tubulysin analogs as payloads for antibody-drug conjugates

Junxiang Jia, Xiaomai Zhou, Yuanyuan Huang, Hongsheng Xie, Huihui Guo, Shun Gai, Lan Qu, Wenjun Li, Lin Chen, Xing Li, Sanxing Sun, Qingliang Yang, Xiaotao Zhuo, Hangbo Ye, Robert Zhao

Cancer Res (2015) 75 (15_Supplement): 4532.

https://doi.org/10.1158/1538-7445.AM2015-4532

Published: 01 August 2015

View articletitled, Abstract 4532: Functional evaluation of novel Tubulysin analogs as payloads for antibody-drug conjugates

Journal Articles

Abstract 2451: A novel humanized anti-CD40 RabMAb exhibits potent efficacy in preclinical models

Yongke Zhang, Jihong Dai, Yaohuang Ke, Wenjun Li, Qiu Yu, Mingzhen Li, Lifeng Feng, Zhiqiang An, Guo-Liang Yu, Weimin Zhu

Cancer Res (2010) 70 (8_Supplement): 2451.

https://doi.org/10.1158/1538-7445.AM10-2451

Published: 15 April 2010

View articletitled, Abstract 2451: A novel humanized anti-CD40 RabMAb exhibits potent efficacy in preclinical models

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5732: DXC020, a novel anti-CD54 antibody conjugate with a functional linker, exhibits potent anti-tumor efficacy

Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, and efficacy

Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations

Abstract 2864: DXA023-G017, a bispecific PD-1/VEGF conjugate elicits potent anti-tumor efficacy in preclinical studies

Abstract 1661: Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor

Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation

Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy

Abstract 5705: Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing pCDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

Abstract 1883: A MUC1 antibody-conjugated with a tubulysin B analog, DXC005, demonstrates excellent synergistic effect in combination with gemcitabine for treatment of pancreatic tumors

Abstract 6581: DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer

Abstract 1884: DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies

Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Abstract 4553: DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer

Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma

Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells In Vivo

Abstract 829: Chemoprevention of oxidative stress-associated oral carcinogenesis by sulforaphane depends on NRF2 and the isothiocyanate moiety

Abstract 4532: Functional evaluation of novel Tubulysin analogs as payloads for antibody-drug conjugates

Abstract 2451: A novel humanized anti-CD40 RabMAb exhibits potent efficacy in preclinical models

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only